ASRT stock forecast
Our latest prediction for Assertio Therapeutics, Inc.'s stock price was made on the Nov. 12, 2019 when the stock price was at 0.73$.
In the short term (2weeks), ASRT's stock price should outperform the market by 6.41%. During that period the price should oscillate between -8.99% and +20.21%.
In the medium term (3months), ASRT's stock price should outperform the market by 13.53%. During that period the price should oscillate between -18.37% and +49.92%.Get email alerts
About Assertio Therapeutics, Inc.
Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL.
At the moment the company generates 213M USD in revenues.
On its last earning announcement, the company reported a loss of -0.74$ per share.
The book value per share is 3.43$
Three months stock forecastNov. 12, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|